GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » US Stem Cell Inc (OTCPK:USRM) » Definitions » Inventory Turnover

US Stem Cell (US Stem Cell) Inventory Turnover : 5.00 (As of Dec. 2022)


View and export this data going back to 2008. Start your Free Trial

What is US Stem Cell Inventory Turnover?

Inventory Turnover measures how fast the company turns over its inventory within a year. It is calculated as Cost of Goods Sold divided by Total Inventories. US Stem Cell's Cost of Goods Sold for the three months ended in Dec. 2022 was $0.01 Mil. US Stem Cell's Average Total Inventories for the quarter that ended in Dec. 2022 was $0.00 Mil. US Stem Cell's Inventory Turnover for the quarter that ended in Dec. 2022 was 5.00.

Days Inventory indicates the number of days of goods in sales that a company has in the inventory. US Stem Cell's Days Inventory for the three months ended in Dec. 2022 was 18.25.

Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue. US Stem Cell's Inventory-to-Revenue for the quarter that ended in Dec. 2022 was 0.05.


US Stem Cell Inventory Turnover Historical Data

The historical data trend for US Stem Cell's Inventory Turnover can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

US Stem Cell Inventory Turnover Chart

US Stem Cell Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Inventory Turnover
Get a 7-Day Free Trial Premium Member Only Premium Member Only 25.90 26.44 9.85 10.40 24.00

US Stem Cell Quarterly Data
Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22
Inventory Turnover Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4.50 7.00 7.00 5.00 5.00

US Stem Cell Inventory Turnover Calculation

US Stem Cell's Inventory Turnover for the fiscal year that ended in Dec. 2022 is calculated as

Inventory Turnover (A: Dec. 2022 )
=Cost of Goods Sold / Average Total Inventories
=Cost of Goods Sold (A: Dec. 2022 ) / ((Total Inventories (A: Dec. 2021 ) + Total Inventories (A: Dec. 2022 )) / count )
=0.024 / ((0 + 0.001) / 1 )
=0.024 / 0.001
=24.00

US Stem Cell's Inventory Turnover for the quarter that ended in Dec. 2022 is calculated as

Inventory Turnover (Q: Dec. 2022 )
=Cost of Goods Sold / Average Total Inventories
=Cost of Goods Sold (Q: Dec. 2022 ) / ((Total Inventories (Q: Sep. 2022 ) + Total Inventories (Q: Dec. 2022 )) / count )
=0.005 / ((0.001 + 0.001) / 2 )
=0.005 / 0.001
=5.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


US Stem Cell  (OTCPK:USRM) Inventory Turnover Explanation

Inventory Turnover measures how fast the company turns over its inventory within a year. A higher Inventory Turnover means the company has light inventory. Therefore the company spends less money on storage, write downs, and obsolete inventory. If the inventory is too light, it may affect sales because the company may not have enough to meet demand.

1. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

US Stem Cell's Days Inventory for the three months ended in Dec. 2022 is calculated as:

Days Inventory =Average Total Inventories (Q: Dec. 2022 )/Cost of Goods Sold (Q: Dec. 2022 )*Days in Period
=0.001/0.005*365 / 4
=18.25

2. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

US Stem Cell's Inventory to Revenue for the quarter that ended in Dec. 2022 is calculated as

Inventory-to-Revenue=Average Total Inventories (Q: Dec. 2022 ) / Revenue (Q: Dec. 2022 )
=0.001 / 0.02
=0.05

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Usually retailers pile up their inventories at holiday seasons to meet the stronger demand. Therefore, the inventory of a particular quarter of a year should not be used to calculate Inventory Turnover. An average inventory is a better indication.


US Stem Cell Inventory Turnover Related Terms

Thank you for viewing the detailed overview of US Stem Cell's Inventory Turnover provided by GuruFocus.com. Please click on the following links to see related term pages.


US Stem Cell (US Stem Cell) Business Description

Traded in Other Exchanges
N/A
Address
1560 Sawgrass Corporate Parkway, 4th Floor, Sunrise, FL, USA, 33323
US Stem Cell Inc is a biotechnology company engaged in the discovery and development of autologous cell therapies for the treatment of chronic and acute heart damage. Its product includes MyoCell, a clinical therapy designed to populate regions of scar tissue within a patient's heart with autologous muscle cells, or cells from a patient's body, for the purpose of improving cardiac function in chronic heart failure patients. The company's discoveries include multiple cell therapies in various stages of development that repair damaged tissues throughout the body due to injury or disease so that patients may return to a normal lifestyle.
Executives
Murphy William P Jr director 13794 NW 4TH STREET, SUITE 212, SUNRISE FL 33325
Gregory Knutson director 14855 ABERDEN STREET NE, HAM LAKE MN 55304
Mark P Borman director 5240 WASHBURN AVENUE SOUTH, MINNEAPOLIS MN 55410
Charles A Hart director 19345 RHINESTONE STREET NW, ANOKA MN 55303
Sheldon T. Anderson director 1121 CRANDON BLVD., APT. D-103, KEY BISCAYNE FL 33149
Kristin C Comella officer: Chief Science Officer 1310 LEEWARD WAY, WESTON FL 33327
A Jones Lee director 54 LOCKE LAKE RD, FRIDLEY MN 55432
Karl Groth director 1160 FIFTH AVENUE, SUITE 207, NEW YORK NY 10029
Matthew J Fendrich officer: Vice President,Sales&Marketing 482 PEACOCK LANE SOUTH, JUPITER FL 33458
Alan P Timmins director 1111 MAIN STREET, SUITE 600, VANCOUVER WA 98660
Bruce C Carson director 11850 COTTONWOOD STREET NW, COON RAPIDS MN 55448
Howard J Leonhardt director, 10 percent owner, officer: Executive Chairman & CTO 13794 NW 4TH STREET, SUITE 212, SUNRISE FL 33325
Bromley R Scott officer: VP of Public Relations 13794 NW 4TH STREET, SUITE 212, SUNRISE FL 33325
Richard Iii Spencer director 13794 NW 4TH STREET, SUITE 212, SUNRISE FL 33325
Mike Tomas director 13794 NW 4TH STREET, SUITE 212, SUNRISE FL 33325

US Stem Cell (US Stem Cell) Headlines

From GuruFocus

USRM Chief Science Officer Featured on YourVoice™ America

By PRNewswire PRNewswire 10-01-2018

Northstar Biotech and USRM BOD Members Reinvest in the Company

By ACCESSWIRE ACCESSWIRE 02-23-2021

USRM Chief Science Officer Featured on One Radio Network

By PRNewswire PRNewswire 01-15-2019

Court Reports Favorable Judgment in California Stem Cell Case

By ACCESSWIRE ACCESSWIRE 09-01-2022

USRM Oral Argument in Appeal from FDA Enforcement Action

By ACCESSWIRE ACCESSWIRE 01-19-2021

USRM Posts Increase in Revenue and Profit Margin for 2018

By PRNewswire PRNewswire 03-14-2019

USRM Posts Financial Results for First Quarter 2019

By PRNewswire PRNewswire 05-08-2019